Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 20/20 | 0.68 |
| ▸ | EDNRA | P25101 | 20/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.49 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709090 | 0.89 | EDNRB (0.60) | EDNRBEDNRA | |
| SCHEMBL6712225 | 0.88 | EDNRB (0.62) | EDNRBEDNRA | |
| SCHEMBL6707560 | 0.87 | EDNRB (0.66) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL6708974 | 0.86 | EDNRB (0.56) | EDNRBEDNRA | |
| SCHEMBL6707529 | 0.85 | EDNRB (0.65) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL6712241 | 0.85 | EDNRB (0.62) | EDNRBEDNRANR1I2KCNE1KCNQ1 | |
| SCHEMBL6708688 | 0.82 | EDNRB (0.59) | EDNRBEDNRA | |
| SCHEMBL6710406 | 0.82 | EDNRB (0.56) | EDNRBEDNRA | |
| SCHEMBL6712126 | 0.81 | EDNRB (0.61) | EDNRBEDNRA | |
| SCHEMBL9369015 | 0.81 | EDNRB (0.76) | EDNRBEDNRANR1I2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034076-A1 | Novel carbamates and carbamides, production and use thereof as endothelin receptor antagonists | ABBOTT GMBH & CO. KG (DE) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034076-A1 | Novel carbamates and carbamides, production and use thereof as endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | EDNRB 2/4885EDNRA 1/4885NR1I2 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.